Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii crawled date : 2022 - 10 - 27 save search
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Published: 2022-10-27 (Crawled : 22:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -6.88%
edg-5506 treatment trial therapeutics duchenne
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 2.16%
H: 5.56%
C: -7.05%
otx-2002 trial therapeutics
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
Published: 2022-10-27 (Crawled : 14:00) - biospace.com/
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 0.39%
H: 0.78%
C: -0.52%
nbi-1117 schizophrenia study phase 2
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
Published: 2022-10-27 (Crawled : 13:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
| O: 0.0%
H: 0.83%
C: -0.5%
melt-300 pharmaceuticals study phase 2
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Published: 2022-10-27 (Crawled : 11:00) - biospace.com/
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: 1.32%
H: 0.43%
C: -3.46%
symposium trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.